Üçüncü basamak bir hastanede COVID-19 tanılı hastalarda remdesivir deneyimi
Open Access
- 1 January 2023
- journal article
- research article
- Published by Pamukkale University in Pamukkale Medical Journal
- Vol. 16 (1) , 1
Abstract
Purpose: Remdesivir is an adenosine nucleotide analog antiviral drug recommended in these treatment combinations. While vaccine and drug studies are underway in the treatment of COVID-19, remdesivir is also being studied in terms of efficacy, safety, and potential side effects. Therefore, we aimed to share our experiences of patients who were diagnosed with COVID-19 and treated with remdesivir in our hospital. Material method: Patients over 18 years of age, who were diagnosed with COVID-19 in our hospital between March 15 and March 30, 2020, based on positive RT-PCR and/or thoracic computed tomography (CT) results studied from nasopharyngeal samples, were screened retrospectively. Those who had received Remdesivir treatment were included in our study. Results: 23 patients were included in our study. Eighteen (79.2%) of the patients were male and 5 (20.8%) were female. Remdesivir initiation time was 8.4±2.6 days from the onset of symptoms and 6±2.6 days from the time of diagnosis. In the follow-up period, we had to hospitalize 18 patients (78.2%) in the intensive care unit (ICU). 14 (60.8%) needed a mechanical ventilator. Post-treatment follow-up showed that 15 (65.2%) recovered, and 8 (34.8%) resulted in mortality. Conclusion: Since inflammation is as critical as the replication of the virus in the pathogenesis of COVID-19 disease, the use of remdesivir in combination with other antiviral and anti-cytokine therapies may increase the effectiveness. We believe that we need new studies in this regard.Keywords
This publication has 33 references indexed in Scilit:
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialThe Lancet Infectious Diseases, 2018
- Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patientsInfection and Drug Resistance, 2017
- Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii: A Prospective Cohort StudyJournal of Intensive Care Medicine, 2017
- Optimizing colistin dosing: Is a loading dose necessary?American Journal of Health-System Pharmacy, 2017
- Colistin loading dose: evaluation of the published pharmacokinetic and clinical dataInternational Journal of Antimicrobial Agents, 2016
- The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort StudyClinical Infectious Diseases, 2016
- Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative PneumoniaJournal of Intensive Care Medicine, 2016
- Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched SeriesChemotherapy, 2016
- Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and DosingPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005